Pivanex and Docetaxel Combination Therapy for Chemotherapy Resistant Advanced Non-Small Cell Lung Cancer

This study focuses on a specific type of lung cancer known as advanced non-small cell carcinoma of the lung (NSCLC) that resists chemotherapy. The trial aims to understand if combining two drugs, Pivanex and Docetaxel, can offer better results than using Docetaxel alone. Pivanex, a histone deacetylase inhibitor, encourages tumor differentiation and/or apoptosis, and has shown promise in previous trials. Docetaxel is an approved second-line treatment for non-small cell lung cancer. The study hopes to address the challenge of chemotherapy resistance in lung cancer, potentially improving patient care and outcomes. In this open-label, randomized trial, participants with NSCLC who have undergone no more than one prior platinum-containing chemotherapy regimen are divided into two groups. One group receives both Pivanex (intravenously on Days 1-3) and Docetaxel (intravenously on Day 4), while the other group receives only Docetaxel (intravenously on Day 1). Both treatments repeat every 21 days until disease progression or treatment withdrawal. The study evaluates the survival, time to disease progression, tumor responses, and safety profile of patients in both groups to determine the effectiveness and safety of the combined therapy compared to Docetaxel alone.